Medical Industry News Archive

Click here to search our archive

Print using browser

URGENT MEDICINE RECALL: SANDOZ CEFPODOXIME 40mg/5ml Reg No A39/20.1.1/0397 (50ml and 100ml pack sizes)
Sandoz SA (Pty) Ltd in collaboration with the Medicines Control Council are initiating a Class 2, Type B recall on all batches of Sandoz Cefpodoxime 40mg /5ml (50ml and 100ml pack sizes).

Sandoz Cefpodoxime 40mg/5ml powder for oral suspension is an antibiotic used for short- term treatment of lower and upper respiratory tract infections in infants, children and adults.

The product is being recalled due to lower than expected efficacy, high unknown impurities, discolouration and formation of brownish agglomerates on certain batches of Sandoz Cefpodoxime 40mg/5ml tested during stability monitoring.

Use of the product may lead to weakened patient therapy through insufficient anti-infective treatment resulting in: a patient being contagious to others for a longer time, the development and spread of resistant bacterial strains, and significant therapeutic difficulties in eradication of respective bacteria.

In the interest of patient safety, Sandoz SA (Pty) Ltd request that you immediately return all batches of Sandoz Cefpodoxime 40mg/5ml stock without delay to your supplying wholesaler or distributor for full credit.
Sandoz SA (Pty) Ltd would like to thank you for your co-operation and apologise for any inconvenience caused.

Should you have any enquiries in this regard kindly contact the Sandoz Customer Call Centre 0861 SANCAL or 0861 726 225 during office hours and a technical support 24 hour call no 0768114744.

For full prescribing information please refer to package insert approved by Medical Regulatory Authority

Sandoz SA (Pty) Ltd PO Box 154, Isando 1600 Kempton Park, Gauteng South Africa Tel Fax +27 (0) 11 394 3084    Reg No: 1990/001979/07
Directors: R-A Bassoul (Canadian) J-C Dubos (French) M.M Paleja (Singaporean)  
A Novartis Company

You need to be logged in to see more details. Register Now!

Click here for more information .....
Contact: Carla Urbani-Smith, (Responsible Pharmacist)
Telephone: +27 (0) 11 929 9000
Date: Tuesday, February 14, 2012

Archive News Headlines
Lamar launch Sentry C, Sentry D and Sentry M Vitamins (Vitamin C, Vit-D3, Multivitamin)
Boehringer Ingelheim discontinue Pulmison 20 mg tablets (prednisone)
Astellas Pharma launch Betmiga tablets (mirabegron)
Boehringer Ingelheim discontinue Inflanaze 100 Aqueous Nasal Spray (budesonide)
Sanofi - Back in Stock - Lasix 40 mg 30's (furosemide)
Pharma Dynamics launch Peploc OTC (pantoprazole 20 mg)
Pfizer - Out of Stock - Ponstan 50mg/5ml Suspension (mefenamic acid)
Adcock discontinue Ketoflam Capsules 30's (ketoprofen)
Cipla launch Actonel Once-a-Month 150 mg (risedronate)
Sandoz - discontinue - Sandoz Ketoconazole 200 mg tablets
Aspen - Out of Stock - Augmentin SR TAblets (amoxicillin, clavulanic acid)
Aspen - Back in Stock - Duofilm Liquid 15 ml (salicylic acid BP and lactic acid anhydrous)
Aspen discontinue Diotroxin tablets and guidance on the switching of patients (thyroxine sodium, liothyronine sodium)
Aspen - Out of Stock - Ketazol 200 mg Tablets (ketoconazole)
Sanofi - Out of Stock - Lasix 40 mg 30's and 250's (furosemide)
iNova launch Allerguard Allergy Nasal Spray (2% Ectoin, Natural Sea Salt)
Novartis discontinue Lescol® 20 mg and 40 mg Capsules 28's (fluvastatin)
Actor Speciality - launch - Co-Atana™ (Latanoprost/Timolol)
Janssen discontinue Risperdal Quicklet formulation (risperidone)